Quay Pharma is now part of sgs logoopens in a new window

PR

Formulation Considerations for Paediatric Populations  

Several factors must be considered to ensure safety and efficacy when developing a drug formulation…

October 17 2023 - PR

Read More

Overcoming Poor Solubility in Formulation Development 

Overcoming poor solubility is an increasingly common challenge in pharmaceutical and formulation…

October 03 2023 - PR

Read More

Overcoming Obstacles in the Development of Live Biotherapeutic Products

Live Biotherapeutic Products (LBPs) are a promising area of research and development for treating a wide range of…

September 18 2023 - PR

Read More

What is a CDMO? And why partner with one?

A CDMO is a company that provides services to the pharmaceutical and biotechnology industries. These organizations offer…

August 31 2023 - PR

Read More

SGS Quay Pharma’s Facility Brings Formulation and Manufacturing Expertise to North America

The need for comprehensive, technically advanced, and integrated services from contract service providers is needed now more than ever.

October 17 2022 - PR

Read More

Careers in the USA at SGS Quay Pharma

Find your next role at SGS Quay Pharma in the USA

August 26 2022 - PR

Read More

Careers in the UK at SGS Quay Pharma

Find your next role at SGS Quay Pharma in the UK

August 26 2022 - PR

Read More

SGS Quay Pharma Receives Queen’s Award for Industry

SGS Quay Pharma has received its Queen’s Award for Enterprise. The award was presented by…

August 08 2022 - PR

Read More

SGS’s Quay Pharma Collaborates to Develop New Oral Medicine for Inflammatory Bowel Disease

SGS’s Quay Pharma has partnered with Intract Pharma, CPI and Pharmidex to successfully…

July 18 2022 - PR

Read More

New Hampshire Pharmaceutical Development and Clinical Manufacturing Facility Nears Completion

We will soon open our Hudson, NH, pharmaceutical development and clinical manufacturing facility.

July 12 2022 - PR

Read More
Older Entries